X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Filspari (sparsentan) is a once-daily oral medication, designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II). It is approved for the treatment of IgA Nephropathy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Filspari (sparsentan) is a once-daily oral medication, designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II). It is approved for the treatment of IgA Nephropathy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
Under the agreement, Renalys will bring Filspari (sparsentan), a dual endothelin angiotensin receptor antagonist for the treatment of IgA nephropathy, to patients in Japan and other countries in Asia.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Renalys Pharma
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 25, 2024
Details:
TVT-058 (pegtibatinase) is a novel investigational enzyme replacement therapy which is being evaluated in phase 3 clinical trials for the treatment of classical homocystinuria (HCU).
Lead Product(s): Pegtibatinase
Therapeutic Area: Genetic Disease Product Name: TVT-058
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
Filspari (sparsentan) is an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with IgAN. It is being investigated for focal segmental glomerulosclerosis.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
Under the agreement, Mirum will purchase Travere’s bile acid product portfolio including, Cholbam, indicated for the treatment of bile acid synthesis disorders and Chenodal, indicated for the treatment of radiolucent stones in the gallbladder.
Lead Product(s): Cholic Acid
Therapeutic Area: Genetic Disease Product Name: Cholbam
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mirum Pharmaceuticals
Deal Size: $445.0 million Upfront Cash: $210.0 million
Deal Type: Divestment July 17, 2023
Details:
TVT-058 (pegtibatinase) is a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU), currently advancing in the Phase 1/2.
Lead Product(s): Pegtibatinase
Therapeutic Area: Genetic Disease Product Name: TVT-058
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
Filspari (sparsentan) is an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with IgAN. It is being investigated for focal segmental glomerulosclerosis.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CSL Vifor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
Filspari (sparsentan), a once-daily oral medication is designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II), and is the first and only non-immunosuppressive therapy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $230.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 03, 2023
Details:
Filspari (sparsentan), a once-daily oral medication is designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II), and is the first and only non-immunosuppressive therapy.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 28, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
